IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

BRUCE A. HAY, ET AL.

APPLICATION NO.: NOT YET ASSIGNED

Examiner: David Lukton

(anticipated)

FILING DATE:

HEREWITH

Group Art Unit: 1653

(anticipated)

TITLE: SOMATOSTATIN ANTAGONISTS and AGONISTS THAT ACT AT THE SST SUBTYPE 2 RECEPTOR

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. \S 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445. A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: September 8, 2003

E. Victor Donahue Attorney for Applicant(s)

Reg. No. 35,492

Pfizer Inc.

Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5755 (212)733 -2739

USERS/DOCS\LA21952\LPEVD\4\$Q%01! DOC / 210918 / PC11862B INFO DISC STMT-HAY 9/8/03

INFORMATION DISCLOSURE CITATION ATTY. DOCK								KET NO	NO. PC11862B SERIAL NO. Not					ssigned		
(Use several sheets if necessary)						API	APPLICANT Bruce Hay, et al.									
							FILING DATE September 8, 2003				GROUP Not Assigned					
							PATENT	DOCU	MENTS							
EXAMINER INITIAL			DOCUMENT NUMBE				;R		DATE	DATE NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	us	5	9	3	6	0	8	9	8/10/99	Carpino, et	al.		Ì			
					FO	REIG	N PATE	NT DO	UMENTS	3						
DOCUMENT NUMBER									DATE	COUNTRY CLASS			SUBCLASS	TRANSI	ATION	
													 	YES	NO	
<u>.</u>	wo	9	9	6	4	4	0_	1	12/16/99	PCT/US			ļ	<u> </u>	-	
	wo	9	8	4	4	9	2	2	10/15/98	PCT/US				L_	<u> </u>	
	wo	9	8_	4	5	2	88	5	10/15/98	PCT/US					L	
	wo	9	. 8	4	4	9	2	_ 1	10/15/98	PCT/US						
			OTHE	R DOCU	JMENTS	(Inclu	ıding Au	thor, Tit	le, Date, F	Pertinent Pag	es, E	c.)				
		Sadaf	Sadaf Farooqu et al., "The Therapeutic Value of Somastatin and Its Analogues" Pituitary Vol. 2, pp. 79-88 (1999)													
	\top	Yoges	Yogesh C. Patel, et al., "Somatostatin Receptors", TEM, Vol. 8, No. 10, (1997) pages 398-404													
-	+	Simon	Simon J. Hocart, et al., "Potent Antagonists of Somatostatin: Synthesis and Biology"; J. Med. Chem. Vol. 41, pp. 1146-1154													
	\dagger		Susan P. Rohrer, et al., "Rapid Identification of Subtype-Selective Agonists of the Somatostatin Receptor Through Combinatorial													
		Henni	Chemistry' Science Vol. 282, pp. 737-740; (1998) Henning Granbæk, et al. 'Potential Role of Octreotide in the Treatment of Diabetes' Prog Basic Clin Pharmacol. Basel, vol. 10, pp. 103-128; (1996)												10,	
		Vicent	pp. 103-125, (1996) Vicente Marriace, et al., "High Basal Gastric Acid Secretions in Somatostatin Receptor Subtype 2 Knockout Mice", American Gastroenterology (1998) 114 pp. 1125-1132													
		Lihu Y	Lihu Yang, et al., "Synthesis and biological activities of potent peptidornimetics selective for somastostatin receptor subtype 2"; Proc. Netl. Acad. Sci. USA, Vol. 95, pp. 10838-10841, (1998)													
		Muhar	Muhammad Zaki, et al., "Somatostatin Receptor Subtype 2 Mediates Inhibition of Gastrin and Histamine Secretion from Human, Dog and Rat Antrum"; Gastroenterology Vol. 111, pp. 919-924 (1996)													
	I		William R. Baumbach, et al., "A Linear Hexpeptide Somatostatin Antagonist Blocks Somatostatin Activity In Vitro and Influences Growth Hormone Release in Rats" Molecular Pharmacology, Vol. 54, pp.864-873 (1998)													
		Torsel	Torsello, Antonio, (<i>Endocrinology</i> 143 (5) 1968, 2002)													
	T	McFac	McFadyen, "Modifications of the cyclic mu receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]NH ₂ (Et): effects on opioid receptor binding and activation" <i>Journal of Peptide Research</i> (2000 Mar) 55 (3) 255-61)													
			Keith, "mu-Opioid receptor inentization: opiate drugs have dirential effects on a conserved endocytic mechanism in vitro and in the mammalian brain" Molecular Pharmacology 53 (3) 377-84, 1998													
										Biochemistry 40,	2860,	2001				
				eceptor ex (1992) 2 (nd the	relationship	to melar	ogenesis ar	d metastatic act	ivity in	B16 me	anoma" Me	lanon	na	
EXAMINER						· DATE CONSIDERED										
		Luned Resea	, "MSH ru arch (May	eceptor ex / 1992) 2 (pression a 1) 5-12	nd the	relationship	to melar	ogenesis ar	d metastatic act	ivity in	B16 me				

Conforms with FORM PTO-F8-A820 NFORMATION DISCLOSURE